Literature DB >> 28708198

The effect of radiofrequency catheter ablation of frequent premature ventricular complexes and arrhythmia burden on left ventricular function.

Agnieszka Wojdyła-Hordyńska1, Oskar Kowalski, Grzegorz J Hordyński, Borislav Dinov, Philipp Sommer, Gerhard Hindricks, Piotr Feusette, Arash Arya.   

Abstract

BACKGROUND: Frequent premature ventricular complexes (PVC) are related to reversible tachycardia-induced cardiomyopathy. However, the role of arrhythmia burden on the outcome of the catheter ablation has not been fully recognised. AIM: The aim of this study was to assess the effect of catheter ablation and PVC burden in patients with and without structural heart disease (SHD) on left ventricular ejection fraction (LVEF).
METHODS: Transthoracic echocardiography was done before and six months after radiofrequency catheter ablation in 109 consecutive patients (61 men, age 55 ± 17 years) with frequent PVCs. Sixty-five (59.6%) patients had underlying SHD.
RESULTS: The catheter ablation procedure was successful in 93 (85.3%) patients. Baseline PVC burden was higher in patients with SHD (22,267 ± 12,934) compared to those without concomitant SHD (15,546 ± 7888), p = 0.005. Nevertheless, patients with LVEF ≤ 50% at baseline presented greater LVEF recovery (from 44% to 56%) than those with LVEF > 50% at baseline after catheter ablation. In both groups, the LVEF improved (p < 0.001); however, no difference was observed be-tween patients with SHD (5.7% ± 1.37%) and without (4.6% ± 0.96%) SHD; p = 0.89. PVC burden was higher in patients with (24,350 ± 2776 PVC/day) compared to those without (17,588 ± 1970 PVC/day) improvement of LVEF. In multivariate regression analysis PVC burden > 20,000/day (but not age, p = 0.95; gender, p = 0.89; presence of SHD, p = 0.53; QRS complex width of the treated PVC, p = 0.21, LVEF before ablation, p = 0.19; and site of origin, p = 47) predicted improvement in LVEF after successful catheter ablation (odds ratio: 3.53; 95% confidence interval: 1.15-10.75; p = 0.023).
CONCLUSIONS: Catheter ablation of frequent PVCs improves left ventricular function in multivariate analysis predicted improvement of LVEF within six months after the successful catheter ablation procedure in patients with PVC burden exceeding 20,000/24 h.

Entities:  

Keywords:  catheter ablation; left ventricular ejection fraction; premature ventricular complex; structural heart disease; ventricular arrhythmia

Mesh:

Year:  2017        PMID: 28708198     DOI: 10.5603/KP.a2017.0058

Source DB:  PubMed          Journal:  Kardiol Pol        ISSN: 0022-9032            Impact factor:   3.108


  4 in total

Review 1.  Premature ventricular complexes: diagnostic and therapeutic considerations in clinical practice : A state-of-the-art review by the American College of Cardiology Electrophysiology Council.

Authors:  Bulent Gorenek; John D Fisher; Gulmira Kudaiberdieva; Adrian Baranchuk; Haran Burri; Kristen Bova Campbell; Mina K Chung; Andrés Enriquez; Hein Heidbuchel; Valentina Kutyifa; Kousik Krishnan; Christophe Leclercq; Emin Evren Ozcan; Kristen K Patton; Win Shen; James E Tisdale; Mohit K Turagam; Dhanunjaya Lakkireddy
Journal:  J Interv Card Electrophysiol       Date:  2019-12-11       Impact factor: 1.900

2.  Atrial and Ventricular Response to Treatment of Premature Ventricular Complexes.

Authors:  Yi-Sheng Chen; Wei-Di Chen; Yin-Huei Chen; Akbarshakh Akhmerov; Hsiang-Chi Wang; Kuan-Cheng Chang; Yen-Nien Lin
Journal:  Acta Cardiol Sin       Date:  2020-09       Impact factor: 2.672

3.  Reversal of premature ventricular complexes induced cardiomyopathy. Influence of concomitant structural heart disease.

Authors:  Mohamed A Abdelhamid; Rania Samir
Journal:  Indian Heart J       Date:  2017-09-01

4.  Diagnostic and prognostic significance of premature ventricular complexes in community and hospital-based participants: A scoping review.

Authors:  Sukardi Suba; Kirsten E Fleischmann; Hildy Schell-Chaple; Priya Prasad; Gregory M Marcus; Xiao Hu; Michele M Pelter
Journal:  PLoS One       Date:  2021-12-23       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.